Key Takeaways
- • Cambridge Associates Investment Director Max English argues that emerging markets equities warrant portfolio reassessment due to reduced diversification benefits stemming from increased benchmark concentration.
- • The concentration effect has diminished the traditional role of emerging markets as a diversification tool within institutional portfolios, challenging conventional allocation frameworks.
- • Investors should evaluate whether current emerging markets equity allocations continue to deliver the risk-adjusted returns and portfolio benefits that historically justified their inclusion in diversified portfolios.
Summary
Emerging markets equities face renewed scrutiny from institutional investors as benchmark concentration has eroded one of the asset class's primary value propositions: diversification benefits. According to Max English, Investment Director at Cambridge Associates, the structural shift toward concentrated benchmarks in emerging markets has fundamentally altered the risk-return profile of the asset class, prompting institutional investors—including pension plans, endowments, and foundations—to reassess their allocation strategies.
The core issue centers on how rising concentration in emerging markets indices has reduced the diversification advantages that typically justify allocating to the asset class alongside developed market equities. Historically, emerging markets provided portfolio benefits through low correlation with U.S. and European equities and exposure to higher-growth economies. However, the concentration phenomenon—whereby a smaller number of large-cap stocks increasingly dominate benchmark weightings—has compressed these diversification gains and created performance dynamics more closely aligned with developed markets.
Cambridge Associates, drawing on over 50 years of institutional investing experience, emphasizes that this development requires rigorous portfolio evaluation. Investors should examine whether their current emerging markets allocations continue to deliver appropriate risk-adjusted returns and genuine diversification benefits relative to their total portfolio construction and risk budgets. The analysis carries particular weight for sophisticated institutional investors managing complex, multi-asset portfolios where every allocation decision must justify its place within the overall framework.
This reassessment does not necessarily signal a wholesale exit from emerging markets but rather a call for more disciplined, evidence-based allocation decisions grounded in current market dynamics rather than historical precedent alone.
The core issue centers on how rising concentration in emerging markets indices has reduced the diversification advantages that typically justify allocating to the asset class alongside developed market equities. Historically, emerging markets provided portfolio benefits through low correlation with U.S. and European equities and exposure to higher-growth economies. However, the concentration phenomenon—whereby a smaller number of large-cap stocks increasingly dominate benchmark weightings—has compressed these diversification gains and created performance dynamics more closely aligned with developed markets.
Cambridge Associates, drawing on over 50 years of institutional investing experience, emphasizes that this development requires rigorous portfolio evaluation. Investors should examine whether their current emerging markets allocations continue to deliver appropriate risk-adjusted returns and genuine diversification benefits relative to their total portfolio construction and risk budgets. The analysis carries particular weight for sophisticated institutional investors managing complex, multi-asset portfolios where every allocation decision must justify its place within the overall framework.
This reassessment does not necessarily signal a wholesale exit from emerging markets but rather a call for more disciplined, evidence-based allocation decisions grounded in current market dynamics rather than historical precedent alone.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.